People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology, Pharmaceuticals, Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CARGO Therapeutics, Inc. | — | Biotechnology | Series C | $68.8M | $1.0B | 2023 |
| Magnus Medical, Inc. | — | Biotechnology | Series C | $64.0M | $153.7M | 2025 |
| Anaptysbio Inc | — | Pharmaceuticals | Series C | $50.8M | $1.4B | 2011 |
| Flexion Therapeutics Inc | — | Biotechnology | Series B | $40.0M | $793.8M | 2012 |
| Engage Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.6M | $238.0M | 2019 |
| Halo Neuro Inc. | — | Other Technology | Series B | $27.9M | $546.3M | 2017 |
| Adynxx, Inc. | — | Pharmaceuticals | Series B | $21.5M | $544.1M | 2016 |
| Inogen Inc | — | Other Health Care | Series A | $14.2M | $194.6M | 2010 |
| Satsuma Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $12.1M | $375.8M | 2016 |
| Spinifex Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $6.2M | $191.0M | 2014 |
Heath Lukatch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Heath Lukatch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Firlik | 2 | 14 |
| Stephen Collins | 2 | 5 |
| Andrew Schwab | 1 | 16 |
| James Topper | 1 | 12 |
| William J. Link | 1 | 10 |
| BRADLEY BOLZON | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Peter Hebert | 1 | 7 |
| Brent Ahrens | 1 | 7 |
| Thomas King | 1 | 6 |
| Carol Gallagher | 1 | 6 |
| Dennis Podlesak | 1 | 6 |
| Elaine Jones | 1 | 6 |
| Amol Sarva | 1 | 6 |
| Declan Doogan | 1 | 6 |
| Robert Hoffman | 1 | 5 |
| James N. Topper | 1 | 5 |
| Rick Orr | 1 | 5 |
| Gerry Brunk | 1 | 5 |
| Gregory Mayes | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.